Education
About Us
Working with TipRanks
Follow Us
Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $5.40
Previous CloseN/A
Volume1.31K
Average Volume (3M)93.40K
Market Cap
$30.14M
Enterprise Value$18.75M
Total Cash (Recent Filing)$12.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 08, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding8,348,161
10 Day Avg. Volume65,583
30 Day Avg. Volume93,401
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-184.53
Enterprise Value/Ebitda-2.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Successful Phase 3 DataStatistically significant Phase 3 mortality reduction materially de-risks the lead asset and strengthens the case for regulatory approval and guideline adoption. Durable subgroup consistency across severity and comorbidities expands addressable populations and supports long-term commercial and partnership prospects.
IP And Commercial-readiness MovesProvisional patents plus manufacturing scale-up and government-funded trials create structural advantages: protectable indications, demonstrated supply readiness, and external funding support. These steps reduce commercialization execution risk and make the program more attractive to partners and payers over time.
Low Leverage / Stronger Equity BaseMinimal debt and an improved equity cushion lower bankruptcy and interest-rate risk, providing financial flexibility to fund late-stage development. This conservative capital structure preserves optionality for partnerships or targeted financing without onerous leverage constraints over the coming months.
Bears Say
No Commercial RevenueAs a development-stage biotech with no commercial sales, the company must convert clinical success into marketed products to generate sustainable cash flow. Until approval and commercialization, persistent operating losses make long-term viability dependent on financing, partners, or milestone deals.
Persistent Negative Cash FlowConsistent negative operating and free cash flow forces reliance on external capital or collaborations to sustain development activities. Even with improved burn versus earlier years, ongoing negative FCF constrains runway and risks dilution or program delays if additional funding is delayed or unfavorable.
Deeply Negative Returns On EquityA roughly -65% ROE signals that invested capital has not translated into returns, reflecting structural unprofitability to date. Until commercial revenues materialize, poor capital efficiency increases investor dilution risk and highlights the dependency on future product launches to justify funding.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $0.72 and its highest was $5.40 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is $30.14M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is May 08, 2026 which is in 62 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Feb 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.245.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Overvalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.26.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 8,348,161 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
16.75% Insiders
0.90% Mutual Funds
33.86% Other Institutional Investors
48.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---